Testing the MenB vaccine safety and immune response in children with rheumatic disease
Part of Bones, joints & muscles, Immune system & allergy clinical trials.
This trial tests a meningitis B vaccine (MenB-4C) in children and young adults with autoimmune rheumatic diseases. It aims to see if the vaccine is safe and works well for these patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and 25 years old.
- You must have an autoimmune rheumatic disease (like juvenile arthritis, lupus, or juvenile dermatomyositis).
- You cannot have already received a MenB (meningococcal B) vaccine.
- You cannot be pregnant, breastfeeding, or have a fever or active infection at the time of vaccination.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a pneumonia vaccine (PCV20) is safe and works well in children and young adults with certain autoimmune rheumatic diseases like juvenile arthritis, lupus, or dermatomyositis. It aims to help protect them from serious infections.
This study tests the safety and immune response of a dengue vaccine in people aged 12–59 with stable autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are on low-dose or no immune-suppressing medications. It also includes healthy volunteers for comparison.
This trial tests a new vaccine called DX-104 to see if it is safe and helps the body fight meningitis B. Healthy adults aged 18-50 can join to help find a better way to prevent this infection.
This study tests a meningococcal B vaccine in adults who have had their spleen removed or have a spleen that doesn't work well (asplenia). It will compare how well the vaccine works in these patients versus healthy adults to see if it provides good protection.
This Phase 3 trial tests how safe and how well the immune system responds to three different meningococcal B vaccine approaches in people who do not have a spleen. It may help future adults like you choose a safer, more effective prevention strategy against meningococcal B infection.
This trial tests two different booster shots for meningitis B in young adults who already got the Bexsero vaccine at least 2.5 years ago. The goal is to see which booster works best to keep you protected.
Hear when a new Autoimmune Rheumatologic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.